# A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia

> **NCT06776510** · PHASE1,PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- Immune Thrombocytopenia
- Treatment

## Interventions

- **DRUG:** nicotinamide adenine dinucleotid/nicotinamide mononucleotide

## Key facts

- **NCT ID:** NCT06776510
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06776510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06776510, "A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06776510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*